Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹4326.36 Cr |
| Offer for Sale | ₹4326.36 Cr |
| Face Value | ₹1 Per Equity Share |
| Price Band | ₹1026.00-1080.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543904 |
| NSE Code | MANKIND |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Kotak Mahindra Capital Co.Ltd. |
| Allotment Status | |
| DRHP | |
| RHP | |
| Final Prospectus | |
| Anchor List |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 13 shares and in multiples thereof
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.
Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.
As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Carry out the Offer for Sale of 40,058,844Equity Shares by the Selling Shareholders aggregating to ₹43,263.55 million | |
| 2 | Achieve the benefits of listing the Equity Shares on the Stock Exchanges. For further details |
| Period Ended | 31 Dec 2022 | 31 Mar 2022 | 31 Dec 2021 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|---|---|
| Assets | 9,273.75 | 9,147.74 | 8,043.88 | 6,372.63 | 5,073.29 |
| Total Income | 6,777.82 | 7,977.58 | 6,218.29 | 6,385.38 | 5,975.65 |
| Profit After Tax | 1,015.98 | 1,452.96 | 1,260.24 | 1,293.03 | 1,056.15 |
| NET Worth | 7,145.89 | 6,155.23 | 5,965.46 | 4,722.00 | 3,485.31 |
| Reserves and Surplus | 7,094.12 | 6,106.06 | 5,916.86 | 4,674.39 | 3,436.34 |
| Total Borrowing | 167.93 | 868.03 | 268.70 | 234.53 | 126.92 |
| Amount in ₹ Crore | |||||
| KPI | |
|---|---|
| ROE | 27.60% |
| ROCE | 26.10% |
| RoNW | 27.70% |
| PAT Margin | 18.67% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 33.20 | |
| P/E (x) | 32.5 | |
| Promoter Holding | 79.00% | 76.50% |
| Market Cap | ₹43263.60 Cr. | |
